Importantly, the BRAF V600 mutation has been confirmed to be the most common and critical oncogenic mutation in AM, and it leads to a continuous overactivation of mitogen-activated protein kinase (MAPK) signaling and its target genes (2, 19, 20). This evidence concerns the gene BRAF and acute myeloblastic leukemia with maturation.